A Phase 2 Trial of KIR Mismatched Unrelated Donor Transplantation Using In Vivo T-cell Depletion with ATG in AML: Children's Oncology Group AAML05P1 Study

AML patients receiving killer immunoglobulin-like receptor (KIR) mismatched  haploidentical HSCT have improved survival. COG AAML05P1 is a prospective phase 2 trial of unrelated donor (URD) HSCT in which KIR typing of donors was available to the treating physician at donor selection, aiming to determine feasibility (defined as the ability to obtain donor samples from unr elated donors and perform and return KIR data before transplant) of prospective selection of KIR mismatched donors and effect on outcomes.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research